Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $39.86 Average Target Price from Analysts

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has received an average rating of “Buy” from the nine brokerages that are currently covering the company, MarketBeat.com reports. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $39.86.

Several research firms have issued reports on ORKA. Wedbush restated an “outperform” rating and issued a $40.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, November 19th. HC Wainwright reissued a “buy” rating and issued a $45.00 target price on shares of Oruka Therapeutics in a report on Friday, February 7th. Finally, Wolfe Research initiated coverage on Oruka Therapeutics in a report on Tuesday, February 4th. They set an “outperform” rating and a $20.00 price objective for the company.

Hedge Funds Weigh In On Oruka Therapeutics

Large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. bought a new stake in Oruka Therapeutics during the 4th quarter worth about $54,000. AlphaCentric Advisors LLC acquired a new stake in shares of Oruka Therapeutics in the 4th quarter valued at approximately $119,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Oruka Therapeutics during the fourth quarter worth $144,000. Squarepoint Ops LLC bought a new position in Oruka Therapeutics during the fourth quarter worth about $236,000. Finally, Wellington Management Group LLP increased its holdings in shares of Oruka Therapeutics by 15.8% in the fourth quarter. Wellington Management Group LLP now owns 95,089 shares of the company’s stock worth $1,844,000 after acquiring an additional 12,952 shares in the last quarter. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Oruka Therapeutics Trading Down 2.2 %

Shares of NASDAQ:ORKA opened at $11.18 on Friday. Oruka Therapeutics has a 52-week low of $10.61 and a 52-week high of $53.88. The company has a 50-day simple moving average of $16.58. The firm has a market capitalization of $391.30 million, a P/E ratio of -1.79 and a beta of 0.77.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.